Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

17.1%

55 terminated/withdrawn out of 322 trials

Success Rate

70.1%

-16.4% vs industry average

Late-Stage Pipeline

6%

20 trials in Phase 3/4

Results Transparency

46%

59 of 129 completed trials have results

Key Signals

67 recruiting59 with results36 terminated19 withdrawn

Enrollment Performance

Analytics

Phase 1
123(43.5%)
N/A
75(26.5%)
Phase 2
61(21.6%)
Phase 4
17(6.0%)
Early Phase 1
4(1.4%)
Phase 3
3(1.1%)
283Total
Phase 1(123)
N/A(75)
Phase 2(61)
Phase 4(17)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (322)

Showing 20 of 322 trials
NCT05137119Phase 4Recruiting

Staphylococcus Aureus Network Adaptive Platform Trial

Role: collaborator

NCT07455409Not ApplicableCompleted

Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy

Role: lead

NCT04554992Phase 1Completed

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

Role: lead

NCT07554417Phase 4Not Yet Recruiting

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

Role: collaborator

NCT04195451Not ApplicableCompleted

Re-Energize Fontan

Role: collaborator

NCT01953900Phase 1Active Not Recruiting

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

Role: collaborator

NCT06307301Phase 1Completed

Study in ALS With Abatacept & IL-2

Role: lead

NCT03057561Not ApplicableCompleted

Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

Role: lead

NCT03820141Phase 2Active Not Recruiting

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Role: lead

NCT07283068Not ApplicableNot Yet Recruiting

IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA

Role: lead

NCT06833866Phase 1Recruiting

Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer

Role: lead

NCT06381791Phase 1Recruiting

CBD for Pain Following Orthopedic Shoulder Surgery

Role: lead

NCT06798623Phase 1Recruiting

Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells

Role: lead

NCT02379520Phase 1Completed

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Role: collaborator

NCT04350359Not ApplicableRecruiting

Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder

Role: collaborator

NCT06176690Phase 1Recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Role: collaborator

NCT07042685Phase 2Recruiting

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Role: lead

NCT06511232Phase 4Recruiting

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction

Role: lead

NCT03236935Phase 1Completed

Phase Ib of L-NMMA and Pembrolizumab

Role: lead

NCT07095712Phase 1Completed

Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

Role: collaborator